Contract Development & Manufacturing (CDMO)
B-MoGen’s ISO 7 cleanrooms now open for business
Are you looking for a CDMO to process your Phase I/II clinical trials or to manufacture GMP grade engineered mammalian cells? Need this service now and need it at a reasonable cost. Our new clean room facility will become fully operational May 1, 2020. B-MoGen now offers process development for any gene modified therapy, cGMP patient processing for Phase I and Phase II clinical trials, and cGMP manufacturing of iPSC cell lines.
B-MoGen state of the art 6,000 square foot cGMP facility is strategically located in Minneapolis, MN, USA. Our US-based suites currently comply with ISO Class 7 (Class 10,000) classification to meet U.S. requirements.
B-MoGen is a leading contract development and manufacturing organization focused on the following:
- Providing our clients with a four month pathway to gene modified therapies without using virus gene modification
- Reducing our customers Cost of Goods (for materials) with gene transfer reagents that are 40% the cost of viral based reagents
- Reducing our clients Cost of Goods sold (for processing patient cells) with clean rooms that are specifically designed at compelling price points
Bio-Techne / B-MoGen New Clean Room Facilities
- 2 Clean Rooms
- 575.000 ft²
- 2 Development Labs
- 1 In-House Quality Control Lab
- 2,300 Employees
The B-MoGen Team
Get the expertise you need and the flexibility you want
B-Mogen’s foundation is a team of highly dedicated experts that combine strong experience in cGMP cell processing with a technology-focused approach and a substantial knowledge of the biotech industry.
B-Mogen’s key management and technical personnel have an average of 7 years experience in cell processing.
Jeff Liter, CEO has tech transferred in many of the leading cell therapies that are in the market place and in the clinic when he was COO of PCT. David Hermanson led Posieda’s development of its manufacturing process. Branden Moriarity and Beau Webber have been instrumental in bringing new gene modified therapies into the clinic through sponsored research programs at the University of Minnesota
Cell Processing and Engineering Services
B-Mogen can provide your therapy with a quicker pathway into the clinic than any other CDMO out there today. offers simplified and lean services to our clients. Rather than working with multiple vendors, our new clean room facility means B-MoGen can offer in house process development for any gene modified therapy, cGMP patient processing for Phase I and Phase II clinical trials, and cGMP manufacturing of iPSC cell lines.
We are exceptionally cognizant of the need to get your therapy into the clinic. Our non-viral gene transfer platform means we can have you in the clinic in four months. We are not only fastidious about patient safety, we are keenly focused on helping you bring down the cost of cell and gene therapies. If you are ready for the next steps, speak with us now.
Call us: +1 888 338 2409
Speak to our experts